Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Revision History For: Cytoclonal Pharmaceutics INC.

No earlier versions found for this Subject.

Return to Cytoclonal Pharmaceutics INC.

This company could have a very bright future.
Paclitaxel production, paclitaxel is the active ingredient in Taxol,marketed by Bristol-Myers Squibb (BMS),sales of US$1.2 billion in 1998. Cytoclonal now has agreements with BMS, re its fermentation production of paclitaxel. CYPH has exclusive worldwide rights to these technologies. Presently, paclitaxel is produced by utilizing components of the Yew tree which results in high cost and limited supply.

PKD. Polycystic Kidney Disease, treatment with paclitaxel.

Novel Rational Drug Design. Quantum Core Technology, QCT.

Peptide Inhibition of Estrogen Receptors on Breast Cancer Cells.

Human Gene Discovery Program. LUNG CANCER PROGRAM.

Anti Sense Technology.

Production of the " IMMORTALITY ENZYME " TELOMARISE.

May we live forever and enjoy the future with cytoclonal,

Share price currently US$7.00. Will we see US$170 soon?

All comments and contributions most welcome,

Regards John Ashbolt.